Drug firm Zydus Cadila Wednesday said it has received final nod from the US health regulator to market generic Acetazolamide injection.
Acetazolamide is effective in the control of fluid secretion, for example in some types of glaucoma, treatment of certain convulsive disorders and promotion of diuresis in instances of abnormal fluid retention such as cardiac edema, it added.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Acetazolamide for injection 500 mg per single-dose vial, Zydus Cadila said in a filing to BSE.
The product will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
It is a generic version of Diamox for injection, it added.
The group now has 262 approvals and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app